ONO PHARMACEUTICAL CO
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT06547528
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Nagoya-shi, Aichi, Japan
🇯🇵Akita University Hospital, Akita-shi, Akita, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 42
- Registration Number
- NCT06542731
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
🇯🇵The Cancer Institute Hospital of JFCR, Koto-ku, Japan
🇯🇵Teikyo University Hospital, Itabashi-ku, Japan
Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06541665
- Locations
- 🇯🇵
Kindai University Hospital, Osakasayama-shi, Osaka, Japan
🇯🇵Institute of Science Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵National Hospital Organization Disaster Medical Center, Midori-cho, Tokyo, Japan
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 65
- Registration Number
- NCT06540261
- Locations
- 🇯🇵
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵Kurashiki Central Hospital, Kurashiki, Okayama, Japan
🇯🇵Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
- Conditions
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 210
- Registration Number
- NCT06538272
- Locations
- 🇯🇵
Nagoya City University Hospital, Aichi, Japan
🇯🇵Nagoya University Hospital, Aichi, Japan
🇯🇵Funabashi Municipal Medical Center, Chiba, Japan
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT06538207
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
🇯🇵Kanagawa Cancer Center, Yokohama-shi, Kanagawa, Japan
🇯🇵Seirei Hamamatsu General Hospital, Hamamatsu-shi, Shizuoka, Japan
Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 204
- Registration Number
- NCT06535009
- Locations
- 🇯🇵
Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT06532344
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo Ku, Japan
🇯🇵Kanagawa Cancer Center, Yokohama-shi, Kanagawa, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 87
- Registration Number
- NCT06532331
- Locations
- 🇯🇵
Aichi Cancer Center, Nagoya-shi, Aichi, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
🇯🇵Kanazawa University Hospital, Kanazawa-shi, Ishikawa, Japan
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 78
- Registration Number
- NCT06525246
- Locations
- 🇯🇵
Kobe City Medical Center General Hospital, Kobe-shi, Hyogo, Japan
🇯🇵The Cancer Institute Hospital Of JFCR, Koto-Ku, Tokyo, Japan
🇯🇵Hyogo College Of Medicine College Hospital, Nishinomiya, Hyogo, Japan